Neuphoria Therapeutics Goodwill and Intangible Assets 2022-2024 | NEUP

Neuphoria Therapeutics goodwill and intangible assets from 2022 to 2024. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Neuphoria Therapeutics Goodwill and Intangible Assets 2022-2024 | NEUP

Neuphoria Therapeutics goodwill and intangible assets from 2022 to 2024. Goodwill and intangible assets can be defined as the sum of all intangible asset fields
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$139.4B
Bristol Myers Squibb (BMY)$115.2B
Gilead Sciences (GILD)$114.5B
Vertex Pharmaceuticals (VRTX)$104.5B
CSL (CSLLY)$84.4B
Regeneron Pharmaceuticals (REGN)$78.6B
GSK (GSK)$70.4B
Argenex SE (ARGX)$37.4B
Alnylam Pharmaceuticals (ALNY)$30.1B
BioNTech SE (BNTX)$27.6B
Biogen (BIIB)$21.9B
Illumina (ILMN)$20.8B
BeiGene (ONC)$18B
Moderna (MRNA)$16.2B
Genmab (GMAB)$13.9B
Incyte (INCY)$13.4B
BioMarin Pharmaceutical (BMRN)$12.7B
Insmed (INSM)$12.5B
Sarepta Therapeutics (SRPT)$11.9B
Bio-Techne Corp (TECH)$11.4B
Exact Sciences (EXAS)$10.5B
Vaxcyte (PCVX)$10.4B
QIAGEN (QGEN)$10.2B
Swedish Orphan Biovitrum (BIOVF)$10.1B
Exelixis (EXEL)$9.7B
Bio-Rad Laboratories (BIO.B)$9.1B
Intra-Cellular Therapies (ITCI)$8.9B
Roivant Sciences (ROIV)$8.8B
Ascendis Pharma (ASND)$8.4B
Repligen (RGEN)$8B